Pharmaceutical - Markets & Marketing, Anti-Arthritics/Rheumatics


Popular Filters

1 to 25 of 34 results

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report


The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm


Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Fidia completes establishment of operations in North America

Fidia completes establishment of operations in North America


Fidia Pharma USA, a wholly-owned subsidiary of privately-held Italian drugmaker Fidia Farmaceutici, says…

Anti-Arthritics/RheumaticsFidia FarmaceuticiManagementMarkets & MarketingPharmaceuticalUSA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA


Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Pipeline innovation bodes well for systemic lupus erythematosus market


While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler


French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA


The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis


The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Japanese launches of subcutaneous injection forms of Pralia and Enbrel, and of Acofide


Among a bunch of Japanese drug launches in the past couple of days, Daiichi Sankyo (TYO: 4568) announced…

AcofideAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaDaiichi SankyodenosumabEnbrelGastro-intestinalsMarkets & MarketingPfizerPharmaceuticalPraliaTakeda PharmaceuticalsZeria Pharmaceuticals

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments


Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Thought leader views on new osteoporosis and osteopenia treatments


US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Switch to anabolics driving osteoporosis market growth


A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

SOBI links with Savient for co-promotion of Kineret in USA


Swedish Orphan Biovitrum (STO: SOBI) says it has entered into an agreement with USA-based Savient Pharmaceuticals…

Anti-Arthritics/RheumaticsInflammatory diseasesKineretLicensingMarkets & MarketingNorth AmericaPharmaceuticalSavient PharmaceuticalsSobiSwedish Orphan Biovitrum

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?


Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Global rheumatology market controlled by Enbrel, Humira and Remicade


The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

Rheumatoid arthritis researchers limber up, says GlobalData


Upcoming therapeutics and an emerging biosimilars industry will improve the lives of Rheumatoid Arthritis…

Anti-Arthritics/RheumaticsBiotechnologyMarkets & MarketingPharmaceuticalResearch

Eli Lilly and Chugai to stop co-marketing of Evista in Japan


The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA


US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021


The rheumatoid arthritis drug market will experience modest growth over the next decade as sales increase…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibGlobalMarkets & MarketingPfizerPharmaceuticalTakeda Pharmaceuticalstofacitinib

Enbrel gets highest rating among RA biologicals by surveyed US patients


For surveyed rheumatoid arthritis (RA) patients on biologic therapy, the benefits outweigh the risks…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelMarkets & MarketingmethotrexateNorth AmericaPfizerPharmaceutical

1 to 25 of 34 results

Back to top